Brazilian Red Propolis Is as Effective as Amoxicillin in Controlling Red-Complex of Multispecies Subgingival Mature Biofilm In Vitro.
Kadmo Azevedo de FigueiredoHelio Doyle Pereira da SilvaStela Lima Farias MirandaFrancisco Jerfeson Dos Santos GonçalvesArlene Pereira de SousaLuciene Cristina de FigueiredoMagda FeresBruno Bueno-SilvaPublished in: Antibiotics (Basel, Switzerland) (2020)
This study investigated the effects of Brazilian Red Propolis (BRP) extract on seven-day-old multispecies subgingival biofilms. Mixed biofilm cultures containing 31 species associated with periodontal health or disease were grown for six days on a Calgary device. Then, mature biofilms were treated for 24 h with BRP extract at different concentrations (200-1600 µg/mL), amoxicillin (AMOXI) at 54 µg/mL (positive control) or vehicle (negative control). Biofilm metabolic activity was determined by colorimetry, and bacterial counts/proportions were determined by DNA-DNA hybridization. Data were analyzed by Kruskal-Wallis and Dunn's tests. Treatment with BRP at 1600, 800 and 400 μg/mL reduced biofilm metabolic activity by 56%, 56% and 57%, respectively, as compared to 65% reduction obtained with AMOXI. Mean total cell counts were significantly reduced in all test groups (~50-55%). Lower proportions of red, green and yellow complex species were observed upon treatment with BRP (400 µg/mL) and AMOXI, but only AMOXI reduced the proportions of Actinomyces species. In conclusion, BRP extract was as effective as AMOXI in killing seven-day-old multispecies biofilm pathogens and did not affect the levels of the host-compatible Actinomyces species. These data suggest that BRP may be an alternative to AMOXI as an adjunct in periodontal therapy. In vivo studies are needed to validate these results.
Keyphrases
- candida albicans
- pseudomonas aeruginosa
- staphylococcus aureus
- biofilm formation
- single molecule
- healthcare
- public health
- cystic fibrosis
- genetic diversity
- circulating tumor
- electronic health record
- anti inflammatory
- mental health
- big data
- combination therapy
- mesenchymal stem cells
- escherichia coli
- cell therapy
- bone marrow
- machine learning
- data analysis
- health information
- deep learning
- multidrug resistant
- atomic force microscopy
- artificial intelligence